Oswald, Brandon M.
DeCamp, Lisa M.
Longo, Joseph https://orcid.org/0000-0002-9580-5105
Dahabieh, Michael S.
Bunda, Nicholas
Johnson, Benjamin K.
Watson, McLane J. https://orcid.org/0000-0001-5778-7690
Ma, Shixin
Preston, Samuel E. J. https://orcid.org/0000-0002-2618-8326
Sheldon, Ryan D. https://orcid.org/0000-0002-1573-9719
Vincent, Michael P.
Ellis, Abigail E. https://orcid.org/0000-0002-8736-8283
Soper-Hopper, Molly T. https://orcid.org/0000-0003-2745-1680
Isaguirre, Christine
Kamarudin, Dahlya
Shen, Hui https://orcid.org/0000-0001-9767-4084
Williams, Kelsey S. https://orcid.org/0000-0002-4163-5075
Crawford, Peter A. https://orcid.org/0000-0001-8597-4426
Kaech, Susan https://orcid.org/0000-0003-1674-1420
Jang, H. Josh https://orcid.org/0000-0001-9654-4448
Lien, Evan C. https://orcid.org/0000-0001-7866-4761
Krawczyk, Connie M. https://orcid.org/0000-0002-2468-5986
Jones, Russell G. https://orcid.org/0000-0003-2250-4675
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA297713)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI165722)
Gouvernement du Canada | Canadian Institutes of Health Research (MFE-181903)
Damon Runyon Cancer Research Foundation (DRG 2495-23)
Article History
Received: 28 May 2025
Accepted: 23 October 2025
First Online: 9 December 2025
Competing interests
: S.M.K. is on the scientific advisory boards and has equity in EvolveImmune Therapeutics, Affini-T Therapeutics, Arvinas and Pfizer. R.G.J. is a scientific advisor to Servier Pharmaceuticals and is a member of the Scientific Advisory Board of Immunomet Therapeutics. The other authors declare no competing interests.